Treatment of Bile Acid Malabsorption With Liraglutide

Sponsor
Filip Krag Knop
Study ID
NCT03955575
Phase
PHASE4
Status
Completed

Conditions

  • Bile Acid Malabsorption

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide 6 MG/ML — DRUG
    Liraglutide as injections.
  • Colesevelam — DRUG
    3 x 625 miligram 2 times a day.

Study Details

Comparing the effect of Liraglutide on bile acid malabsorption, with colesevelam

Key Dates

Start date
Mar 7, 2019
Status verified
Jun 2022
Primary completion
Mar 10, 2021
Completion
May 31, 2022

Study Design

Enrollment
52 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Liraglutide/placebo-colesevelam
    Liraglutide as active and colesevelam as placebo
  • Active Comparator: Placebo-Liraglutide/colesevelam
    Liraglutide as placebo and colesevelam as placebo

Primary Outcome Measure

Change in stool fequency [ Time Frame: 7 weeks ]

Related Studies